Following Aspen Pharmacare’s announcement that it will not be manufacturing the lenacapavir HIV prevention injection and will instead focus on producing alimatravir, Spotlight explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production. The article features infographics produced by AVAC, tracking PrEP price comparisons and alimatravir clinical trials.